Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients

NCT01376804 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01376804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01376804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2011
Completion date
May 31, 2013
Enrollment
57 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation, cytomegalovirus infections